| NCT ID | NCT04548817 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Cutaneous Melanocytic Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2020-09-03 |
| Primary Completion | 2027-09-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2020-09-03 with a primary completion date of 2027-09-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will involve collecting information about the regular medical care you receive for large cutaneous melanocytic nevi (LCMN) or neurocutaneous melanocytosis (NCM).
Eligibility Criteria
Inclusion Criteria: * Patients with LCMN, defined as: * Dark-colored patch of skin present at birth * Can be located anywhere on the individual's skin * May include satellite lesions * May be associated with hypertrichosis OR, in absence of cutaneous involvement: * histologically or radiographically confirmed CNS melanocytosis. * Any age at diagnosis. * Signed informed consent by a patient, or parent/legal guardian. * Deceased patients can be included provided that parent/legal guardian is contacted at least 6 months after the death of the child and not on the child's birthday or anniversary of death. Pathology review at MSK is not mandatory to confirm the diagnosis of LCMN or NCM. We will not require pathology analysis of leptomeningeal deposits in patients where characteristic skin lesions are present and melanosis of the meninges is radiographically evident. However, if pathology samples have already been obtained as part of a patient's evaluation and treatment at another institution, tissue samples will be requested for review and confirmation of the diagnosis. Exclusion Criteria: * Informed consent has not been provided.
Contact & Investigator
Yasmin Khakoo, MD
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT04548817 clinical trial?
This trial is open to participants of all sexes, studying Cutaneous Melanocytic Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04548817 currently recruiting?
Yes, NCT04548817 is actively recruiting participants. Contact the research team at khakooy@mskcc.org for enrollment information.
Where is the NCT04548817 trial being conducted?
This trial is being conducted at Boston, United States, New York, United States.
Who is sponsoring the NCT04548817 clinical trial?
NCT04548817 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Yasmin Khakoo, MD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 100 participants.